Products from BPS Bioscience require a minimum order value above 400€
Applications: Useful for inhibition of PD-1:PD-L1 and PD-1:PD-L2 interactions
Assay Conditions: Antibody was added to PD-1: PD-L1 [Biotinylated] binding assay at various concentrations. Assay was performed according to the protocol in BPS Cat. #72005 or #72006, respectively.
Background: This antibody binds and blocks the activation of the PD-1 receptor. The antibody is humanized, containing a human IgG4 Fc region with an engineered hinge region mutation (S228P) designed to prevent the exchange of IgG4 molecules. This antibody is equivalent to Nivolumab, which has been approved by the FDA for the treatment of melanoma and metastatic squamous non-small cell lung cancer.
Description: Humanized recombinant anti-PD-1 (IgG4) antibody with S228P mutation, expressed in HEK293 cells. This antibody has not been tested with other species.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
Purification: Protein A affinity chromatographyfrom HEK293 supernatants.
Storage Stability: Stable for at least 12 months at -80°C. Store diluted antibody with carrier protein (BSA 0.1 - 0.5%) at 4°C, stable for 2 weeks.
Tags: None
Uniprot: Q15116
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Shinohara, T., et al., Genomics. 1994; 23(3): 704-6. 2. James, E.S., et al., Genes Immun. 2005; 6(5): 430-7.
English
Deutsch
